Physician profile
Scott M Barb
NPI 1609137595
$3,382.82
in general payments reported to CMS, 2019-2025
16 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $37.85 · 2021: $19.34 · 2022: $550 · 2023: $782 · 2024: $580 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $695.57 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $656.55 | 2022-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $516.86 | 2019-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $504.84 | 2019-2025 | Eylea Hd, Eylea |
| Harrow Eye, LLC | $165.38 | 2024 | Iheezo |
| Bausch & Lomb Americas INC. | $148.48 | 2023 | Xipere |
| Genentech, INC. | $144.93 | 2023-2025 | Vabysmo |
| Eyepoint US, INC. | $101.37 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $99.16 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Astellas Pharma Global Development | $92.08 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $91.17 | 2019-2020 | |
| Biogen, INC. | $68.47 | 2022-2024 | Byooviz |
| Coherus Oncology, INC. | $28.22 | 2023 | |
| Astellas Pharma US INC | $27.78 | 2025 | Izervay |
| Alcon Vision LLC | $22.62 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $19.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Barb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.